Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Introducing BPaL: Experiences from countries supported under the LIFT-TB project. Local targets link to admitted publications; unresolved targets remain external evidence.
10.30875/b75dea7e-en
10.30875/b75dea7e-en · 2021 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2016 · External reference
Unresolved reference
2018 · External reference
Treatment of highly drug-resistant pulmonary tuberculosis
10.1056/nejmoa1901814 · 2020 · External reference
Extensively drug-resistant TB as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
10.1016/s0140-6736(06)69573-1 · 2006 · External reference
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection
10.3201/eid1903.120998 · 2013 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
Budgetary impact of using BPaL for treating extensively drug- resistant TB
10.1136/bmjgh-2021-007182 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TB
10.1056/nejmoa2119430 · 2022 · External reference
Unresolved reference
External reference
Introducing bedaquiline: experience from the Challenge TB project
10.5588/ijtld.19.0790 · 2020 · External reference
The experience of bedaquiline implementation at a decentralized clinic in South Africa.
10.5588/pha.16.0037 · 2016 · External reference
Unresolved reference
2015 · External reference
Unresolved reference
External reference
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
10.1056/nejmoa2117166 · 2022 · External reference
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
10.1164/rccm.202107-1779oc · 2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2022 · External reference
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
10.1111/resp.13143 · 2018 · External reference
Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
10.3390/antibiotics12040714 · 2023 · External reference
Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors
10.1183/13993003.01719-2016 · 2017 · External reference
Reply: call for regular susceptibility testing of bedaquiline and delamanid
10.1164/rccm.201605-1065le · 2016 · External reference
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
2023 · External reference
